Lexington biotech plots $86M IPO as key gene therapy trial nears

Nightstar Therapeutics, which has a small headquarters in London and a larger office in Massachusetts, is gearing up for a late-stage study of a rare eye disease drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.